Recent 8-K filings for AKTS

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 11, 2026 20:04 UTC earnings item 2.02item 9.01

  Aktis Oncology Q1 2026 net loss $18.3M; cash $538.5M; Phase 1b trials advancing

source · AKTS on sec.gov